MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES
The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.